<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262769</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000455013</org_study_id>
    <secondary_id>CRUK-ABC-02</secondary_id>
    <secondary_id>EU-205103</secondary_id>
    <secondary_id>ISRCTN82956140</secondary_id>
    <secondary_id>EUDRACT-2004-004882-14</secondary_id>
    <secondary_id>CTA-21266/0005/001</secondary_id>
    <nct_id>NCT00262769</nct_id>
  </id_info>
  <brief_title>Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors</brief_title>
  <acronym>ABC-02</acronym>
  <official_title>Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It&#xD;
      is not yet known whether gemcitabine is more effective with or without cisplatin in treating&#xD;
      cholangiocarcinoma or biliary tract tumors.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying gemcitabine and cisplatin to see how&#xD;
      well they work compared to gemcitabine alone in treating patients with unresectable locally&#xD;
      advanced or metastatic cholangiocarcinoma or other biliary tract tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the overall survival of patients with unresectable locally advanced or&#xD;
           metastatic cholangiocarcinoma or other biliary tract tumors treated with gemcitabine&#xD;
           hydrochloride with vs without cisplatin.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the progression-free survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the toxic effects of these regimens in these patients.&#xD;
&#xD;
        -  Compare quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      participating center, primary site of disease (gallbladder vs bile ducts vs ampulla), prior&#xD;
      therapy (photodynamic therapy [PDT] vs non-PDT therapy vs none), ECOG performance status (0&#xD;
      vs 1 vs 2), and disease status (locally advanced vs metastatic). Patients are randomized to 1&#xD;
      of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and&#xD;
           15. Treatment repeats every 28 days for 6 courses in the absence of disease progression&#xD;
           or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV&#xD;
           over 1½ hours on days 1 and 8. Treatment repeats every 21 days for 8 courses in the&#xD;
           absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, 12 weeks, and after finishing treatment.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for at least 3 years.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 400 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of randomisation till date of death or last date of follow-up (up to 5 years)</time_frame>
    <description>From date of randomisation till date of death or last date of follow-up (up to 5 years)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From date of randomisation till date of death or last date of follow-up (up to 5 years)</time_frame>
    <description>From date of randomisation till date of death or last date of follow-up (up to 5 years)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Before and 12 weeks after completion of treatment</time_frame>
    <description>Quality of life as measured by EORTC Quality of Life Questionnaire Core 30 Items periodically</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>During treatment and follow-up</time_frame>
    <description>Toxicity as measured by NCI CTC periodically. The proportion of patients who experience a toxicity of grade 3 or 4 will be compared between the two arms of the trial.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">324</enrollment>
  <condition>Extrahepatic Bile Duct Cancer</condition>
  <condition>Gallbladder Cancer</condition>
  <arm_group>
    <arm_group_label>A - Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - Gemcitabine and Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine and Cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>25 mg/m2 in 1000 mls 0.9% saline given over 1 hour followed by 500 mls 0.9% saline over 90 mins</description>
    <arm_group_label>B - Gemcitabine and Cisplatin</arm_group_label>
    <other_name>CDDP</other_name>
    <other_name>cis-diamminedichloroplatinum(II)</other_name>
    <other_name>cisplatinum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>1000mg/m2 in 250-500mls 0.9% saline over 30 mins by intravenous infusions on day 1, 8 and 15 (Arm A only) of each 28 (Arm A) or 21 (Arm B) day cycle.</description>
    <arm_group_label>A - Gemcitabine</arm_group_label>
    <arm_group_label>B - Gemcitabine and Cisplatin</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed biliary tract, gallbladder, or ampullary&#xD;
             carcinoma&#xD;
&#xD;
               -  Intra- or extra-hepatic disease allowed&#xD;
&#xD;
          -  Unresectable locally advanced, recurrent, or metastatic disease&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL (transfusion allowed)&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 3 times upper limit of normal (ULN) (5 times ULN if liver metastases are&#xD;
             present)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3 times ULN (5 times ULN if liver metastases are present)&#xD;
&#xD;
          -  Adequate biliary drainage&#xD;
&#xD;
          -  No unresolved biliary tract obstruction&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN&#xD;
&#xD;
          -  Urea &lt; 1.5 times ULN&#xD;
&#xD;
          -  Glomerular filtration rate (GFR) ≥ 45 mL/min&#xD;
&#xD;
               -  If GFR &lt; 60 mL/min, isotope EDTA confirmation of adequate renal function is&#xD;
                  required&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  No active, uncontrolled infection&#xD;
&#xD;
          -  No other severe or uncontrolled systemic disease&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmetastatic basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix treated by cone-biopsy or&#xD;
             resection&#xD;
&#xD;
          -  No psychiatric disorder that would preclude giving informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 6 months since prior adjuvant chemotherapy&#xD;
&#xD;
          -  No prior gemcitabine hydrochloride&#xD;
&#xD;
          -  No prior cisplatin&#xD;
&#xD;
          -  No prior systemic chemotherapy for locally advanced or metastatic disease except&#xD;
             low-dose radiosensitizing chemotherapy in conjunction with radiotherapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Prior radiotherapy for localized disease allowed provided there is clear evidence of&#xD;
             disease progression afterwards&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Prior curative surgery allowed provided there is evidence of nonresectable disease&#xD;
             relapse requiring systemic chemotherapy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapies&#xD;
&#xD;
          -  Prior photodynamic therapy (PDT) allowed provided it was given for localized disease&#xD;
             only (with no evidence of metastatic disease) and resulted in subsequent disease&#xD;
             progression after completion of therapy OR to relieve biliary obstruction in the&#xD;
             presence of metastatic disease&#xD;
&#xD;
               -  PDT must have been completed ≥ 4 weeks ago&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agents&#xD;
&#xD;
          -  No other concurrent, curative anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A. Bridgewater</last_name>
    <role>Study Chair</role>
    <affiliation>University College London (UCL) Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Basingstoke and North Hampshire NHS Foundation Trust</name>
      <address>
        <city>Basingstoke</city>
        <state>England</state>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Infirmary</name>
      <address>
        <city>Carlisle</city>
        <state>England</state>
        <zip>CA2 7HY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Oncology Centre at Cheltenham General Hospital</name>
      <address>
        <city>Cheltenham</city>
        <state>England</state>
        <zip>GL53 7AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derbyshire Royal Infirmary</name>
      <address>
        <city>Derby</city>
        <state>England</state>
        <zip>DE1 2QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Essex</city>
        <state>England</state>
        <zip>CM20 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Royal Hospital</name>
      <address>
        <city>Gloucester</city>
        <state>England</state>
        <zip>GL1 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Royal Hospital at Hull and East Yorkshire NHS Trust</name>
      <address>
        <city>Hull</city>
        <state>England</state>
        <zip>HU8 9HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helen Rollason Cancer Care Centre at North Middlesex Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>N18 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - London</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W12 OHS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Cancer Institute</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1E 6DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College of London Hospitals</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WIT 3AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <state>England</state>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology</name>
      <address>
        <city>Merseyside</city>
        <state>England</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre at Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <state>England</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portsmouth Oncology Centre at Saint Mary's Hospital</name>
      <address>
        <city>Portsmouth Hants</city>
        <state>England</state>
        <zip>PO3 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research Centre at Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital Trust Incorporating Belvoir Park Hospital</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center at Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glan Clwyd Hospital</name>
      <address>
        <city>Rhyl, Denbighshire</city>
        <state>Wales</state>
        <zip>LL 18 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721.</citation>
    <PMID>20375404</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>December 6, 2005</study_first_submitted>
  <study_first_submitted_qc>December 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2005</study_first_posted>
  <last_update_submitted>July 16, 2012</last_update_submitted>
  <last_update_submitted_qc>July 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cholangiocarcinoma of the extrahepatic bile duct</keyword>
  <keyword>recurrent extrahepatic bile duct cancer</keyword>
  <keyword>unresectable extrahepatic bile duct cancer</keyword>
  <keyword>cholangiocarcinoma of the gallbladder</keyword>
  <keyword>recurrent gallbladder cancer</keyword>
  <keyword>unresectable gallbladder cancer</keyword>
  <keyword>metastatic extrahepatic bile duct cancer</keyword>
  <keyword>metastatic gallbladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

